Clinical Trial Update: Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MRI surveillance to reduce symptomatic brain metastases in patients with stage III non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Brain Metastases, Nonsmall Cell Lung Cancer Stage III | Phase 2 | Status: RECRUITING